Antibody Synthesis


Antibody Synthesis service provides synthesis and cloning of your antibody heavy/light chain sequences into any custom vector in as few as 6 days. This is the fastest turnaround time on the market. Our high-quality results are paired with FREE recombinant antibody expression optimization and FREE cloning vector storage for up to 2 years.

GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences offers a customer-friendly antibody synthesis service with Ph.D.-level technical support to alleviate common synthesis obstacles and streamline your antibody discovery research.


Precision Antibody Discovery

Leverage machine learning to increase candidates and improve antibody production


What is the process of Antibody Synthesis?

Antibody synthesis is the production of antibodies – proteins created by the immune system of a host — in response to an antigen, a foreign body that enters the host. The production of an antibody involves several steps:

  • Preparation of the immunogen
  • Immunization
  • Creation of a hybridoma
  • Collection
  • Screening
  • Isotyping
  • Purification of the antibody
  • Antibody labeling for direct use

Antibody Synthesis Features & Benefits

Rapid Turnaround Time – Starting at just 6 days to meet your project deadlines
Quality Control – Stringent quality control with guaranteed 100% sequence accuracy
Vector Storage – FREE cloning vector storage for up to 2 years
Codon Optimization – Optimize recombinant antibody expression using our FREE codon optimization tool
Large-Scale Plasmid Prep – Multiple plasmid DNA preparation options from ug to mg
Ph.D.-Level Customer Support – Our dedicated Project Management team provides consultation and support for your project, from start to finish


Synthetic Gene Length Turnaround Time (TAT)
<500 bp
6-8 Business Days
501-750 bp
751-1500 bp 8-10 Business Days
Custom cloning No Additional TAT


Enter to win $1,000 towards GENEWIZ
Multiomics & Synthesis Solutions*

*Terms and conditions apply

Synthesize all types of DNA Sequences for Antibody Research

Advancements in recombinant monoclonal antibody (rAb) technology have led to the development of a variety of engineered antibody molecules for research, diagnosis, and therapy. With over 10 years of expertise in gene synthesis and cloning, Azenta has supported numerous antibody discovery and development projects, including researchers developing broadly anti-virus monoclonal antibodies [1], bispecific recombinant antibodies [2], anticancer Fc-engineered human monoclonal antibody [3, 4], and much more.

Figure 1. Synthetic DNA in antibody development

Recombinant antibodies can be developed using de novo synthesis of recombinant VDJ light chain and heavy chain sequences. Synthetic DNA can be also used in humanized or other recombinant antibodies such as single-chain variable fragment (scFv), single domain antibody (sdAb), fragment antigen binding mAb (Fab), trifunctional antibody, etc.


“I have always had great customer service from Azenta, received great products with a good price. It allows me to do other things in the lab instead of spending time cloning, etc.”
- Researcher from Cincinnati Children's Hospital Medical Center

“Good quality, customer support, and expediated delivery to help me to meet the deadline.”
- Principal Investigator from a top pharmaceutical company


[1]Xiao H, Guo T, Yang M, et al. Light chain modulates heavy chain conformation to change protection profile of monoclonal antibodies against influenza A viruses. Cell Discov. 2019;5:21. Published 2019 Apr 16. doi:10.1038/s41421-019-0086-x

[2]Ahmed M, Lopez-Albaitero A, Pankov D, et al. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 2018;3(4):e97805. Published 2018 Feb 22. doi:10.1172/jci.insight.97805

[3] Qi X, Li F, Wu Y, et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019;10(1):2141. Published 2019 May 20. doi:10.1038/s41467-019-10088-1

[4]Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Cancer Cell. 2016;29(6):820–831. doi:10.1016/j.ccell.2016.05.001


Gene-to-Discovery Solutions

AAV Packaging, Custom mRNA Synthesis, Lentivirus Packaging, Recombinant Antibody Production


*Samples must arrive at the GENEWIZ New Jersey laboratory before 10:00 am EST to qualify for Same Day service. Note that direct-sequencing templates are not available for our Same Day service.

Gene Synthesis Ordering Guide

Email | Phone (1-877-436-3949, Ext. 3)